Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance
Based on the data from this study, poor in vitro susceptibility rates for amikacin and meropenem-vaborbactam against contemporary ceftazidime-avibactam-resistant non-CP-CRE were observed. In contrast, aztreonam-avibactam, colistin and tigecycline appear to be reasonable options for the management of infections caused by ceftazidime-avibactam-resistant non-CP-CRE.
Authors
- I-Min Liu (ORCID: https://orcid.org/0000-0001-5399-8853)
- Chih‐Cheng Lai (ORCID: https://orcid.org/0000-0002-6334-2388)
- Po-Chuen Hsieh
- Chia‐Ying Liu (ORCID: https://orcid.org/0000-0002-8698-683X)
- Yu-tsung Huang
- Kang Huang
- Shio‐Shin Jean
Institutions
- National Sun Yat-sen University (TW)
- Min Sheng General Hospital (TW)
- Tajen University (TW)
- Far Eastern Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Lunghwa University of Science and Technology (TW)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/jac/dkaf375
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00